News|Articles|August 8, 2024
Biopharmaceutical Frontiers
Author(s)Solvias
Daniel Galbraith, Chief Scientific Officer (CSO) of Solvias provided a comprehensive picture to Pharmaceutical Technology of the current landscape of cell and gene therapy advancements. The discussion covers important regulatory guidance, technological landmarks, and how Solvias is impacting the current market.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
Everything to Know about BMS & NVidia’s AI Supercomputer
2
Can AI Fix Pharma's Last-Mile Delivery Blind Spot?
3
From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026
4
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
5